Working together to diminish the impact of psychiatric illness

News

new-clue-to-autism-found-inside-brain-cells
New clue to autism found inside brain cells

Study indicates activity of mGlu5 receptors plays role in memory, social and cognitive problems.

More »
new-target-explored-for-psychiatric-drug-development
New target explored for psychiatric drug development

Naturally occurring molecule could offer new treatments for schizophrenia and other mental illnesses.

More »
brain-differences-seen-in-depressed-preschoolers
Brain differences seen in depressed preschoolers

Study from Washington University researchers shows elevated activity in the amygdala of preschoolers with depression.

More »
medication-and-talk-therapy-for-anxiety-in-seniors
Medication and talk therapy for anxiety in seniors

New multicenter study finds escitalopram and cognitive behavioral therapy, when used in combination, are effective in treating anxiety disorders in older adults.

More »
human-connectome-project-releases-data-on-brain-connectivity
Human Connectome Project releases data on brain connectivity

Initial data from groundbreaking study includes brain imaging and behavioral information.

More »
Stay up to date with the Institute

About the Institute
about-1
Drug
Discovery
about-2
Novel Therapeutics
about-3
Lifestyle Interventions
about-4
Clinical Affiliates

Launched in 2012 with visionary support of Andrew and Barbara Taylor and the Crawford Taylor Foundation, the Taylor Family Institute for Innovative Psychiatric Research at Washington University School of Medicine in St. Louis is focused on changing the landscape of mental health.

Our Approach
approach-1
Step 1
Novel
Chemistry
approach-2
Step 2
Drug discovery / synthesis
approach-3
Step 3
Biochemical
testing
approach-4
Step 4
Testing on ion
channels and
brain cells
approach-5
Step 5
Testing in circuits
approach-6
Step 6
Testing in animal models
approach-7
Step 7
Scaled up chemistry
approach-8
Step 8
Toxicity testing
approach-9
Step 9
Human trials

The Institute brings together a broad, innovative network of collaborators dedicated to drug discovery, the development of novel therapeutics, lifestyle interventions and clinical applications to improve the outcomes of individuals with psychiatric illnesses.

The Collaborators
collaborators-1
10 investigators
collaborators-2
6 laboratories
collaborators-3
4 departments

Harnessing the expertise of four departments and six laboratories at Washington University School of Medicine, Phase I of the Institute’s work focuses on neurosteroids, compounds that alter brain function and are naturally produced by the nervous system.

A unique industry partnership with Sage Therapeutics will allow opportunities for novel biochemical targets to travel more rapidly down the drug development pipeline and into clinical application.

The Impact
impact-1
Psychiatric disorders affect more than
80 million Americans.
impact-2
Psychiatric
disorders affect about
25%
of people around the world.
estimates from the World Health Organization

Psychiatric disorders involve dysfunction in brain networks, which manifest in cognitive, emotional and motivational symptoms in disorders that include depression, bipolar disorder, anxiety disorders, substance use disorders and schizophrenia.

Effective treatments for individuals with psychiatric disorders will come from understanding and altering the function of brain networks. Since its founding in 2012, the Taylor Family Institute for Innovative Psychiatric Research has drawn upon a longstanding legacy in understanding the biology, neuroanatomy and genetics of psychiatric disorders in its mission to prevent and cure psychiatric illness.

The Future

The pipeline from initial drug discovery to clinical application and treatment is long and requires significant funding resources. While the number of those touched by psychiatric disorders is great, government funding for the development of novel treatments is limited.

Your support to help cure and prevent psychiatric illness is vital.
Join with us in our mission to help change the future.

Ways to Give
zorumski
C.F. Zorumski, MD
Samuel B. Guze Professor and Head of Psychiatry

Psychiatry is and will continue to be the major beneficiary of advances in neuroscience and genetics during the 21st century.

mennerick
Steven Mennerick, PhD
Professor of Psychiatry

The Taylor Family Institute is uniquely positioned to promote a pipeline of discovery to treatment.  Conventional support considers only fragments of this pipeline.

akk
Gustav Akk, PhD
Assistant Professor of Anesthesiology, Molecular Cell Biology

The unique synergy of interactions among Washington University faculty uniquely positions the Taylor Family Institute to advance the diagnosis, treatment and care of psychiatric illness.

reichert-2
David Reichert, PhD
Associate Professor of Radiology

Institute members collaborate on the use of computer modeling to understand how atypical compounds bind to and effect receptors in a manner different from the commonly studied molecules.

izumi
Yukitoshi Izumi, MD, PhD
Research Professor of Psychiatry

Innovative development of new treatments will require sustained effort over the years. It is challenging to conduct this type of research based solely on governmental funding.

evers-2
Alex Evers, MD
Henry E.Mallinckrodt Professor and Head of Anesthesiology

Currents drugs target a very small number of proteins and are not adequately effective. We aim to expand the range of target proteins — opening up the possibility of different and more effective treatments.

wozniak
David Wozniak, PhD
Research Professor of Psychiatry, Director, Animal Behavior Core

Our goal is to construct models that will not only be valid but also reliable and efficient for the testing of many different neurosteroid drugs, which may have efficacy in treating mental illness.